论文部分内容阅读
2008年10月17日,上海美迪西生物医药有限公司和美国医药研发巨头MPI RESEARCH公司共同投资的美迪西普亚医药科技(上海)有限公司在上海张江举行了开业典礼。该公司是按照美国食品药品监督管理局(FDA)的GLP标准以及国际实验动物管理评估及认证协会(AAALAC)的要求兴建的高科技企业,主要从事生物医药的临床前研究技术服务以及相关的技术咨询。美迪西普亚医药科技公司的落成,标志着我国在这一领域与国际市场进一步接轨。以陈春麟博士为学科带头人的高效的医药技术专业研究团队在业内赢得了业绩良好的声誉,已占据国内临床前新药研发外包CRO行业前列。公司董事长比尔·巴菲特表示,健康、富裕和长寿是全世界人民的共同追求。而健康和长寿离不开药品。而药品的安全和有效是第一位的,新药的研发尤其如此。
On October 17, 2008, Mediphia Pharmaceutical Technology (Shanghai) Co., Ltd., a joint venture invested by Shanghai Medicilon Biopharmaceutical Co., Ltd. and American pharmaceutical research and development giant MPI RESEARCH, held an opening ceremony in Zhangjiang, Shanghai. The company is a high-tech company established under the FDA’s GLP standard and the International Association of Laboratory Animal Assessment and Accreditation (AAALAC) and is principally engaged in the biomedical preclinical research and technical services and related technologies advisory. The completion of MediPhia Pharmaceutical Technology Corporation marks the further convergence of our country with the international market in this field. Dr. Chen Chunlin as a leader in the efficient pharmaceutical technology research team won a good reputation in the industry, has occupy the forefront of new domestic R & D outsourcing CRO industry forefront. Bill Buffett, the company’s chairman, said health, prosperity and longevity are the common aspirations of people throughout the world. And health and longevity can not be separated from drugs. The safety and effectiveness of medicines is the priority, especially for new drug research and development.